Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.
暂无分享,去创建一个
F. Montorsi | M. Graefen | A. Briganti | R. Karnes | B. Tombal | A. Tizzani | M. Spahn | J. Walz | P. Gontero* | S. Joniau | C. Bangma | F. Abdollah | H. Van Poppel | D. Frohneberg | B. Kneitz | G. Marchioro | B. Frea | N. Passoni | R. Karnes | P. Gontero
[1] Rosalia Viterbo,et al. Long‐term survival after radical prostatectomy versus external‐beam radiotherapy for patients with high‐risk prostate cancer , 2011, Cancer.
[2] F. Mottaghy,et al. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. , 2011, European urology.
[3] C. Simone. Re: Firas Abdollah, Maxine Sun, Rodolphe Thuret, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011;59:88-95. , 2011, European urology.
[4] U. Capitanio,et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. , 2011, European urology.
[5] J. Kaouk,et al. Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. , 2011, Urology.
[6] P. Scardino,et al. Pathological results and rates of treatment failure in high‐risk prostate cancer patients after radical prostatectomy , 2011, BJU international.
[7] D. Penson,et al. Trends in the treatment of localized prostate cancer using supplemented cancer registry data , 2011, BJU international.
[8] M. Cooperberg,et al. Comparative risk‐adjusted mortality outcomes after primary surgery, radiotherapy, or androgen‐deprivation therapy for localized prostate cancer , 2010, Cancer.
[9] J. Eastham,et al. What is the optimal management of high risk, clinically localized prostate cancer? , 2010, Urologic oncology.
[10] B. Tombal,et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. , 2010, European urology.
[11] P. Scardino,et al. Variations among experienced surgeons in cancer control after open radical prostatectomy. , 2010, The Journal of urology.
[12] N. Willich,et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] B. Trock,et al. What are the outcomes of radical prostatectomy for high-risk prostate cancer? , 2009, Urology.
[14] C. Lawton. Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial , 2010 .
[15] J. Eastham,et al. Role of radical prostatectomy in the treatment of high-risk prostate cancer , 2008, Current urology reports.
[16] M. Kattan,et al. Radical prostatectomy in men aged ≥70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram , 2008, BJU international.
[17] F. Saad,et al. Prostate volume and adverse prostate cancer features: fact not artifact. , 2007, European journal of cancer.
[18] C. Roehrborn,et al. Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. , 2007, European urology.
[19] F. Montorsi,et al. Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. , 2007, European urology.
[20] P. Scardino,et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. , 2007, The Journal of urology.
[21] A. D'Amico,et al. Guideline for the management of clinically localized prostate cancer: 2007 update. , 2007, The Journal of urology.
[22] P. Scardino,et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. , 2006, The Journal of urology.
[23] M. Zelefsky. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911) , 2006 .
[24] Jorge Yao,et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.
[25] M. Piérart,et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) , 2005, The Lancet.
[26] Michael W Kattan,et al. Judging new markers by their ability to improve predictive accuracy. , 2003, Journal of the National Cancer Institute.
[27] M Bolla,et al. EAU guidelines on prostate cancer. , 2001, European urology.
[28] Thomas Wiegel,et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.
[29] F. Montorsi,et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. , 2011, European urology.
[30] M. Cooperberg,et al. Erratum: Comparative risk‐adjusted mortality outcomes after primary surgery, radiotherapy, or androgen‐deprivation therapy for localized prostate cancer , 2011 .
[31] C. Lawton. Duration of Androgen Suppression in the Treatment of Prostate Cancer , 2010 .
[32] T. Roskams,et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. , 2007, European urology.